A5080555627- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Cancer Cells and Metastasis
- Liver physiology and pathology
- Lymphatic System and Diseases
- Cancer, Hypoxia, and Metabolism
- Biosimilars and Bioanalytical Methods
- Cytokine Signaling Pathways and Interactions
- Neonatal Respiratory Health Research
- Nanowire Synthesis and Applications
- Nanofabrication and Lithography Techniques
Candiolo Cancer Institute
2019-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2022-2024
University of Turin
2022-2024
Albert Einstein College of Medicine
2018
Abstract Transport of tissue-derived lymphatic fluid and clearance by draining lymph nodes are pivotal for maintenance homeostasis in the body immune-surveillance self- non-self-proteomes. Yet a quantitative analysis nodal filtration proteome present has not been reported. Here we quantified efficiency composite proteomic load using label-free isotope-labeling pre-nodal post-nodal samples collected direct cannulation. These results were extended quantitation fluorophore-labeled proteins,...
Interferon-induced expression of programmed cell death ligands (PD-L1/PD-L2) may sustain tumour immune-evasion. Patients featuring MET amplification, a genetic lesion driving transformation, benefit from anti-MET treatment. We explored if MET-targeted therapy interferes with Interferon-γ modulation PD-L1/PD-L2 in MET-amplified tumours. and signalling pathways downstream or were analysed lines patient-derived organoids, basal condition, upon stimulation, after therapy. PD-L1 PD-L2 upregulated...
HER2 amplification occurs in approximately 5% of colorectal cancer (CRC) cases and is associated only partially with clinical response to combined human epidermal growth factor receptor 2 (HER2)/epidermal (EGFR)-targeted treatment. An alternative approach based on adoptive cell therapy using T cells engineered anti-HER2 chimeric antigen (CAR) proved be toxic due on-target/off-tumor activity. Here we describe a combinatorial strategy safely target carcinoembryonic (CEA) expression CRC...
Chimeric Antigen Receptor (CAR) therapy targeting carcinoembryonic antigen (CEA/CEACAM5) is a promising strategy for colorectal cancer (CRC). CAR-T cells, however, carry significant side effects, and the fact that CEA also expressed at low levels in normal tissues makes CAR-NK cells safer alternative, offering reduced toxicity while maintaining effective anti-tumor activity. Despite this potential, systems remain underexplored. In study, we generated evaluated clones of NK-92 cell line...
Aberrant activation of the MET receptor in cancer is sustained by genetic alterations or, more frequently, transcriptional upregulations. A fraction MET-amplified or mutated tumors are sensible to targeting agents, but their responsiveness typically short-lasting, as secondary resistance eventually occurs. Since absence usually not a tumor driver, overexpressing not/poorly responsive targeted therapies. Consequently, vast majority exhibiting still represent an unmet medical need.Here we...
Abstract HER2 amplification occurs in about 5% of colorectal cancers (CRC) and is only partially associated with clinical response to combined HER2/EGFR targeted treatment. An alternative approach, based on Adoptive Cell Therapy (ACT) using T cells engineered anti-HER2 Chimeric Antigen Receptor (CAR), proved toxic due "on-target off-tumor" activity. Therefore, we developed a combinatorial ACT strategy safely target CRC synNotch-based artificial regulatory network. A synthetic Notch receptor...
Abstract Colorectal cancer (CRC) is the third most common worldwide, with highly variable prognosis and response to treatment. A large subset of patients does not respond standard treatments or develops resistance. As an alternative, adoptive immunotherapy based on chimeric antigen receptor (CAR)-transduced immune cells has been proposed, however significant adverse events. We therefore evaluated alternative CAR targets already tested in other tumour types, employed natural killer cell line...
Colorectal cancer (CRC) is the third most common worldwide, with highly variable prognosis and response to treatment. A large subset of patients does not respond standard treatments or develops resistance. As an alternative, adoptive immunotherapy based on chimeric antigen receptor (CAR)-transduced immune cells has been proposed, however significant adverse events. We therefore evaluated alternative CAR targets already tested in other tumour types employed natural killer cell line NK-92 for...
Cancer cell dissemination is sustained by cell-autonomous and non-cell-autonomous functions. To disentangle the role of HGF (Hepatocyte Growth Factor) MET ligand/receptor axis in this complex process, we genetically knocked out gene cancer cells which not oncogenic driver. In way, evaluated contribution HGF/MET to independently its direct activities tumor microenvironment. The lack expression MET-/- has been proved molecular characterization. From a functional point view, stimulation was...
Abstract Adoptive immunotherapy based on chimeric antigen receptor (CAR)-T cells has led to successful treatment of some hematological malignancies, but it remains extremely challenging for solid tumors, mostly because “on-target off-tumor” toxicity, as observed in the case anti-HER2 CAR-T colorectal cancer (CRC) with HER2 amplification. To enable adoptive against HER2-amplified CRC, we therefore considered a combinatorial strategy synNotch-based artificial regulatory network. A synthetic...
<h3>Background</h3> Adoptive immunotherapy based on chimeric antigen receptor (CAR)-T cells has led to successful treatment of different hematological malignancies. However, it remains extremely challenging for solid tumors, mostly because "on-target off-tumour" toxicity, as observed in the case anti-HER2 CAR-T HER2-amplified colorectal cancer (HER2<sub>amp</sub> CRC).<sup>1</sup> To enable adoptive against HER2<sub>amp</sub> CRC, we therefore considered a combinatorial strategy...